This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

30 Mar 2021

TCR2 bets on lead candidate with new cell therapy manufacturing facility

The US facility in Rockville is expected to accelerate the company’s commercial-scale manufacturing timelines of gavo-cel

Clinical stage cell therapy company TCR2 Therapeutics has signed a long-term, full-building lease for an existing 85,000-sq. ft manufacturing facility in Rockville, Maryland, which is ready for Current Good Manufacturing Practice (cGMP) build-out.

The site will support clinical and commercial production of gavo-cel — the company's lead TRuC-T cell product — with a capacity to treat several thousand cancer patients annually.

Gavo-cel is currently in a Phase I/II clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

TCR2 said leasing an existing manufacturing facility would save the company time and capital, and would help to accelerate the company’s commercial-scale manufacturing timelines with production anticipated in 2023.

According to TCR2 Therapeutics' President and CEO, Garry Menzel, the company was keen to secure a "dedicated US manufacturing facility" having been encouraged by "consistent early clinical benefit and manageable safety profile" experienced by patients treated with gavo-cel.

The new facility will allow the company to directly leverage its cell therapy process development expertise and control its end-to-end production supply chain. Upon completion, It will provide space for commercial and clinical manufacturing, quality control laboratories and offices.

TCR2 is designing the cell therapy facility to utilize semi-automated and functionally closed systems which aim to provide cGMP manufacturing and, simultaneously, optimize the reliability of its cell therapy products, and reduce manufacturing costs and vein-to-vein time. The flexible layout will allow production of gavo-cel and other emerging cell therapies in the TRuC-T cell pipeline.

Related News